Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28937223 | 0.78 | HDAC8 (0.40) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL20087381 | 0.76 | TDP1 (0.44) | HDAC8CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL31251087 | 0.76 | HDAC8 (0.43) | HDAC8HDAC1HDAC2HDAC6 | |
| SCHEMBL30737059 | 0.76 | HDAC8 (0.43) | HDAC8HDAC1HDAC2HDAC6 | |
| SCHEMBL26337010 | 0.75 | CES1 (0.34) | HDAC8CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL23301373 | 0.74 | HDAC8 (0.37) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL21590083 | 0.74 | GMNN (0.47) | CYP2C9CYP2C19 | |
| SCHEMBL25493092 | 0.74 | HDAC8 (0.31) | HDAC8 | |
| SCHEMBL25272001 | 0.73 | HDAC8 (0.33) | HDAC8 | |
| SCHEMBL23768567 | 0.72 | CYP2C9 (0.40) | HDAC8CYP1A2CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CHO Pharma Inc. (TW) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CSGALNACT1, ST6GAL1, PA2G4 | HDAC8 2790/4885CYP1A2 626/4885CYP2C9 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.